A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2151-2159

  Sunagawa, Yoichi ^a,c,d   Morimoto, Tatsuya ^d   Wada, Hiromichi ^c   Takaya, Tomohide ^a,c   Katanasaka, Yasufumi ^d   Kawamura, Teruhisa ^c   Yanagi, Shigeki ^a   Marui, Akira ^a   Sakata, Ryuzo ^a   Shimatsu, Akira ^c   Kimura, Takeshi ^a   Kakeya, Hideaki ^b   Fujita, Masatoshi ^a   Hasegawa, Koji ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Curcumin; Heart failure; Hypertrophy

Indexed keywords

CURCUMIN; ENALAPRIL; PROTEIN P300; TRANSCRIPTION FACTOR GATA 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CELL SIZE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ECHOCARDIOGRAPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE CELL; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; MALE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; VASCULAR FIBROSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CURCUMIN; E1A-ASSOCIATED P300 PROTEIN; ELECTROCARDIOGRAPHY; ENALAPRIL; HEART FAILURE; HISTONE DEACETYLASE INHIBITORS; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 80052146116     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1072     Document Type: Article

References (40)

1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
3. Francis GS, Chu C. Compensatory and maladaptive responses to cardiac dysfunction. Curr Opin Cardiol 1994; 9: 280-288.
4. Katz AM. Maladaptive growth in the failing heart: The cardiomyopathy of overload. Cardiovasc Drugs Ther 2002; 16: 245-249.
5. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997; 59: 551-571.
6. Frey N, Olson EN. Cardiac hypertrophy: The good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
7. Chien KR. Stress pathways and heart failure. Cell 1999; 98: 555-558.
8. Hasegawa K, Meyers MB, Kitsis RN. Transcriptional coactivator p300 stimulates cell type-specific gene expression in cardiac myocytes. J Biol Chem 1997; 272: 20049-20054.
9. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, et al. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 2000; 275: 13721-13726.
10. Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T, et al. FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. J Biol Chem 2004; 279: 37640-37650.
11. Kolodziejczyk SM, Wang L, Balazsi K, DeRepentigny Y, Kothary R, Megeney LA. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 1999; 9: 1203-1206.
12. Paradis P, MacLellan WR, Belaguli NS, Schwartz RJ, Schneider MD. Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes. J Biol Chem 1996; 271: 10827-10833.
13. McKinsey TA, Olson EN. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet 2004; 20: 206-213.
14. Dai YS, Markham BE. p300 Functions as a coactivator of transcription factor GATA-4. J Biol Chem 2001; 276: 37178-37185.
15. Backs J, Olson EN. Control of cardiac growth by histone acetylation/ deacetylation. Circ Res 2006; 98: 15-24.
16. Wei JQ, Shehadeh LA, Mitrani JM, Pessanha M, Slepak TI, Webster KA, et al. Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300. Circulation 2008; 118: 934-946.
17. Yanazume T, Hasegawa K, Morimoto T, Kawamura T, Wada H, Matsumori A, et al. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 2003; 23: 3593-3606.
18. Takaya T, Kawamura T, Morimoto T, Ono K, Kita T, Shimatsu A, et al. Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes. J Biol Chem 2008; 283: 9828-9835.
19. Sunagawa Y, Morimoto T, Takaya T, Kaichi S, Wada H, Kawamura T, et al. Cyclin-dependent kinase-9 is a component of the p300/ GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes. J Biol Chem 2010; 285: 9556-9568.
20. Miyamoto S, Kawamura T, Morimoto T, Ono K, Wada H, Kawase Y, et al. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation 2006; 113: 679-690.
21. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferasedependent chromatin transcription. J Biol Chem 2004; 279: 51163-51171.
22. Morimoto T, Sunagawa Y, Kawamura T, Takaya T, Wada H, Nagasawa A, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest 2008; 118: 868-878.
23. Feng B, Chen S, Chiu J, George B, Chakrabarti S. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 2008; 294: 1119-1126.
24. Morimoto T, Sunagawa Y, Fujita M, Hasegawa K. Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin. Circ J 2010; 74: 1059-1066.
25. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 2009; 133: 145-151.
26. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: New strategies justified by recent clinical trials. Int J Cardiol 1994; 43: 151-163.
27. Pitt B. Therapy of left ventricular dysfunction: Implications of recent therapeutic trials and future directions for therapy. Schweiz Med Wochenschr 1993; 123: 342-348.
28. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
29. Tambara K, Sakakibara Y, Sakaguchi G, Lu F, Premaratne GU, Lin X, et al. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation 2003; 108: 259-263.
30. Takaya T, Wada H, Morimoto T, Sunagawa Y, Kawamura T, Takanabe-Mori R, et al. Left ventricular expression of lectin-like oxidized low-density lipoprotein receptor-1 in failing rat hearts. Circ J 2010; 74: 723-729.
31. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstifield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for the Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-1064.
32. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
33. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57: 84-95.
34. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990; 67: 1355-1364.
35. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: Critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-423.
36. Liu YH, Liu LY, Wu JX, Chen SX, Sun YX. Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice. J Cardiovasc Pharmacol 2006; 47: 82-88.
37. Epstein J, Sanderson IR, Macdonald TT. Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies. Br J Nutr 2010; 103: 1545-1557.
38. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007; 4: 807-818.
39. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-4499.
40. Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 183-189.